Flash Finance

Syngene International LimitedSYNGENECorporate

Healthcare Diagnostics & Research Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹386.10
MCap ₹15,541 Cr · P/E 70.3
Syngene International Limited — Stock analysis & AI research Syngene International Limited — Multibagger AI analysis Syngene International Limited — Seasonality — best & worst months Syngene International Limited — Technical indicators & charts Syngene International Limited — Technical setup — score, trend, support & resistance Syngene International Limited — Descending Channel pattern forming Syngene International Limited — Live exchange announcements
📋 Small Cap Stocks List 📈 MACD Bullish Crossover📈 SuperTrend Bullish Signal📈 Strong Trend Stocks (ADX > 25)📈 Multi-Timeframe Bearish Stocks📈 Accumulation (OBV Rising) ⚖️ vs Indegene 🏭 Healthcare sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹736 Cr
Sales · Jun 2026
-15.8% YoY
₹91 Cr
Operating Profit · Jun 2026
-56.0% YoY
12.3%
OPM % · Jun 2026
-47.9% YoY
₹-9 Cr
Net Profit · Jun 2026
-110.4% YoY
₹-0.22
EPS · Jun 2026
-110.2% YoY

📝 Syngene International Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Syngene International Limited reported revenue of ₹736 crore for the quarter ended June 2026 (Q1 FY27), down 15.8% from ₹874 crore in the same quarter last year, and down 29.0% sequentially over the March 2026 quarter.

The company reported a net loss of ₹9 crore, against a net profit of ₹87 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.22.

Operating profit stood at ₹91 crore — an operating margin (OPM) of 12.3%, compared with 23.6% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Syngene International Limited posted revenue of ₹3,738 crore, a growth of 2.6% over FY25, with a net profit of ₹317 crore (down 36.2% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹3,600 crore with a net profit of ₹221 crore.

Valuation snapshot

At the current price of ₹386.10, SYNGENE has a market capitalisation of ₹15,541 crore and a trailing P/E of about 70.3.

Within the Diagnostics & Research industry, it is the 3rd-largest of the 3 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 52.59%, foreign institutional investors (FIIs) 10.14%, domestic institutional investors (DIIs) 29.30%, public shareholders 7.56% of Syngene International Limited.

Promoter holding slipped from 52.68% to 52.59% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹15,541 Cr
Current Price ?
₹386.1
P/E ?
70.32above ind
Industry P/E ?
70.20
P/B ?
3.21
P/S ?
4.32
P/FCF ?
28.41
Enterprise Value ?
₹15,999 Cr
EV/EBITDA ?
19.93
PEG ?
N/A
Earnings Yield ?
2.2%
Dividend Yield ?
0.33%
Profitability & Returns
Sales (TTM) ?
₹3,600 Cr
OPM ?
22.3%
Profit after tax (TTM) ?
₹221 Cr
EPS (TTM) ?
₹5.49
ROCE ?
10.0%
ROE ?
4.6%
ROA ?
3.1%
Growth
Sales — latest qtr ?
₹736 Cr
PAT — latest qtr ?
₹-9 Cr
YoY qtr sales growth ?
-15.8%
YoY qtr profit growth ?
-110.4%
Sales growth (3y) ?
5%
Sales growth (5y) ?
11%
Profit growth (3y) ?
-7%
Profit growth (5y) ?
0%
Financial Health
Debt ?
₹458 Cr
Debt to Equity ?
0.09
Interest Coverage ?
9.6
Current Ratio ?
N/A
Ownership
Promoter holding ?
52.59%
Change in promoter holding ?
-0.09%
Pledged percentage ?
N/A
Market
Return 3 months ?
-7.5%
Return 6 months ?
-11.6%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 7869948089108549177908919441,0188749119171,036736 -15.8% -29.0%
Operating Profit 23131421225423231717024528434420620020930391 -56.0% -70.0%
Other Income 172324222916181618191815-551625 +42.9% +58.1%
Interest 141010131113121312161213121210 -17.2% -20.0%
Depreciation 9596102105108111107111109106111116114112112 +0.9% +0.2%
Profit Before Tax 1402311231511382091011371812401018528196-19 -119.0% -109.8%
Net Profit 1101799311611218976106131183876715148-9 -110.4% -106.1%
EPS 2.744.462.332.902.784.701.892.643.274.562.161.670.373.67-0.22 -110.2% -106.0%
OPM % 29.4% 31.6% 26.2% 27.9% 27.1% 34.6% 21.5% 27.5% 30.1% 33.8% 23.6% 22.0% 22.8% 29.2% 12.3% -47.9% -57.9%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹3,642 Cr ₹3,738 Cr ₹3,600 Cr +2.6%
Operating Profit ₹1,042 Cr ₹918 Cr ₹803 Cr -11.8%
OPM % 28.60% 24.57% 22.30% -14.1%
NPM % 13.62% 8.47% 6.14% -37.8%
Other Income ₹72 Cr ₹-6 Cr ₹1 Cr -108.8%
Depreciation ₹433 Cr ₹453 Cr ₹454 Cr +4.8%
Interest ₹53 Cr ₹49 Cr ₹47 Cr -8.5%
EBIT ₹609 Cr ₹465 Cr ₹349 Cr -23.6%
PBT ₹660 Cr ₹410 Cr ₹290 Cr -37.8%
Tax ₹164 Cr ₹15 Cr ₹-10 Cr -91.1%
Net Profit ₹496 Cr ₹317 Cr ₹221 Cr -36.2%
EPS ₹12.36 ₹7.87 ₹5.49 -36.3%
Material Cost ₹869 Cr ₹240 Cr ₹178 Cr -72.4%
Employee Cost ₹984 Cr ₹262 Cr ₹259 Cr -73.4%
Extraordinary Items ₹32 Cr — ₹-14 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 401402402403 +0.2%
Reserves 3,2173,8564,3244,436 +2.6%
Borrowings 815555578458 -20.8%
Other Liabilities 1,3981,3391,4911,757 +17.8%
Total Liabilities 5,8316,1526,7967,055 +3.8%
Fixed Assets 2,6672,8502,8023,005 +7.2%
CWIP 1778381,2661,040 -17.9%
Investments 918548647741 +14.5%
Other Assets 2,0691,9162,0812,268 +9.0%
Total Assets 5,8316,1526,7967,055 +3.8%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 8241,0421,168915 -21.7%
Cash from Investing Activity -653-494-744-860 -15.6%
Cash from Financing Activity -342-551-142-215 -51.4%
Net Cash Flow -172-4281-160 -156.9%
Free Cash Flow 305553398547 +37.4%
CFO/OP 102%115%123%107% -13.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 61465350 -5.7%
Inventory Days 141946056 -6.7%
Days Payable 109100136138 +1.5%
Cash Conversion Cycle 9240-23-32 -39.1%
Working Capital Days -14-27-51-24 +52.9%
ROCE % 15%15%14%10% -28.6%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 52.68%52.68%52.68%52.68%52.59% -0.2%
FIIs 16.51%16.31%14.96%13.91%10.14% -27.1%
DIIs 24.05%24.62%25.83%26.44%29.30% +10.8%
Public 6.45%6.08%6.22%6.69%7.56% +13.0%
Others 0.31%0.30%0.29%0.29%— —
No. of Shareholders 1,42,3101,36,0611,31,7501,35,6051,34,008 -1.2%

⚖️ Peer comparison

Industry: Diagnostics & Research · 3 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SAILIFE SAI LIFE ₹1,585.00 33,664 95.7 2,181 343 29.0% 15.7% 29.4% 105.3% 3.8% 18.2%
2 LALPATHLAB Dr. Lal ₹1,897.00 31,676 58.5 2,892 546 29.0% 18.9% 12.3% 3.4% 19.1% 27.2%
3 SYNGENE Syngene International ₹383.10 15,420 69.8 3,600 221 22.3% 6.1% 2.6% -36.2% -15.8% -110.4%
❓ Frequently asked questions
What was Syngene International Limited's revenue in Q1 FY27?
Syngene International Limited reported revenue of ₹736 crore for the quarter ended June 2026 (Q1 FY27), down 15.8% from ₹874 crore in the same quarter last year, and down 29.0% sequentially over the March 2026 quarter.
What was Syngene International Limited's net profit in Q1 FY27?
The company reported a net loss of ₹9 crore, against a net profit of ₹87 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.22.
What is SYNGENE's market capitalisation and P/E ratio?
At the current price of ₹386.10, SYNGENE has a market capitalisation of ₹15,541 crore and a trailing P/E of about 70.3.
Who owns Syngene International Limited? (shareholding pattern)
As of Sep 2026, promoters held 52.59%, foreign institutional investors (FIIs) 10.14%, domestic institutional investors (DIIs) 29.30%, public shareholders 7.56% of Syngene International Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI